Author of

• 16751

  +

  P1.05 - Poster Session with Presenters Present (ID 457)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Early Stage NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/05/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 16828

    +

    P1.05-077 - Outcome of N2 Disease in NSCLC - A Single Institution Experience (ID 5041)

    14:30 - 14:30  |  Author(s): B. Čučević
    • Abstract

    Background:
    There are many different therapy options available for stage IIIA-N2 NSCLC patients that were set by the NCCN guidelines. That is why we decided to evaluate outcome of different management strategies.
    
    Methods:
    Medical records of the patients diagnosed with lung cancer in Clinical hospital center Zagreb, Department for respiratory diseases Jordanovac during the year 2012 and 2013 were retrospectively collected and reviewed. Median overall survival (mOS) was measured and analyzed using the Kaplan-Meier and log-rank test.
    
    Results:
    There were 147 patients diagnosed with stage IIIA–N2 NSCLC, out of which 105 were male (71.4%), with median age 63 (40-102). Most of them were ex-smokers (54.4%), while only 9.5% never smoked cigarettes. Most of them had very good performance status at the time of diagnosis (ECOG 0-1 91.9%). 78 (53.1%) of the patients were diagnosed with adenocarcinoma, 62 (42.2%) with planocellular carcinoma, 6 (4.1%) with NSCLC-NOS and only 1 (0.7%) with adenosquamous carcinoma. mOS for all diagnosed lung cancer patients was 9 months and for NSCLC 8 months. mOS for IIIA-N2 NSCLC was 14 months. Our patients were treated with chemotherapy in 40.8% of the cases (mOS 11 months); sequential chemotherapy and irradiation in 25.2% (mOS 17 months); surgery, sequential chemotherapy and irradiation in 14.3% (mOS 26 months); surgery and adjuvant chemotherapy in 4.1% (mOS 15 months) and neoadjuvant chemotherapy and surgery in 1.4% (mOS 34 months) of the cases, while only 1.4% of all patients were treated with only surgical resection (mOS 4 months); (p=0.001).
    
    Conclusion:
    We analyzed the data collected at our department to assess the difference in outcomes of different strategies in IIIA – N2 management. The most of our patients were treated with platinum-based doublets only, followed by sequential chemotherapy and irradiation as a second most frequent therapy option. Only 21.8% of the patients were treated with surgery only or surgery combined with other forms of treatment. Only 1 patient underwent concurrent chemoradiation. The difference in overall survival between different therapy options showed highest mOS in patients treated with neoadjuvant chemotherapy and surgery followed by surgery and sequential chemotherapy and irradiation. Sequential chemotherapy and irradiation was superior to chemotherapy. The limitation of our study was a small number of patients in this specific subgroup, as well as small number of patients who underwent concurrent chemoradiation.